Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Genetics

Background:

• Limited effective therapies exist for reducing triglyceride levels.
• Olezarsen is an antisense oligonucleotide targeting apolipoprotein C-III mRNA, a key inhibitor of triglyceride clearance.

Purpose of the Study:

• To evaluate the efficacy and safety of Olezarsen in patients with moderate or severe hypertriglyceridemia.
• To assess the placebo-adjusted change in triglyceride levels at 6 months.

Main Methods:

• Phase 3, international, double-blind, randomized, placebo-controlled trial.
• 1349 patients with moderate or severe hypertriglyceridemia received monthly subcutaneous Olezarsen (50-mg or 80-mg) or placebo.
• Primary outcome: least-squares mean percent change in triglyceride level from baseline to 6 months.

Main Results:

• Olezarsen significantly reduced triglyceride levels compared to placebo.
• The 50-mg dose showed a placebo-adjusted reduction of -58.4 percentage points (P<0.001).
• The 80-mg dose showed a placebo-adjusted reduction of -60.6 percentage points (P<0.001).

Conclusions:

• Olezarsen treatment led to a significantly greater reduction in triglyceride levels than placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk.
• The incidence of serious adverse events was similar across treatment groups.
• Olezarsen represents a promising therapeutic option for managing hypertriglyceridemia.